SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB ...

A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions caused by tissue stress and inflammation, including neuropathic pain and ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

Rentosertib, an AI-generated small molecule targeting Traf2- and Nck-interacting kinase, was safe and improved FVC in ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Shares of Artelo Biosciences edged up after the company said preclinical data for its ART12.11 drug candidate showed cognitive benefits over existing antidepressants. The stock rose 63% to $16.35 ...